Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 07, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in Maxim Group Women’s Health Panel

SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will...
June 30, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience,...
June 24, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022

SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced partial adjournment of its 2022 Annual Meeting of...
June 06, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in the 2022 BIO International Convention

SAN DIEGO, June 06, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
May 16, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
May 12, 2022 06:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update

$39.3 million in cash and cash equivalents at March 31, 2022Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022Organon exclusive global license agreement for...
May 11, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces NIH Grant Award

Supports research to define end-user preferences among U.S. women to informthe design of long-acting injectable hormonal contraception Daré is developing novel injectable formulations of etonogestrel...
May 05, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
April 14, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in Upcoming Conference

SAN DIEGO, April 14, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
April 12, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1

Prior Phase 1 Study Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause Current Phase 1/2 Study will Collect Symptom Relief and...